SPRAVATO THERAPY
Find Relief Through Spravato® Nasal Spray
For Treatment-Resistant Depression (TRD) & Major Depressive Disorder (MDD)
Intranasal Spravato®
Intranasal ketamine is a new medication administered through the nose used as a depression treatment and for suicidal ideation. Patients self-administer the medication through a nasal spray and are monitored in a comfortable office setting. Ketamine has been shown to increase the growth of brain cells, which is one reason researchers think it works so rapidly. Intranasal ketamine is FDA-approved and considered safe and effective for many people who have not responded to more traditional treatments.
Advanced Medical psychiatry Group is proud to offer Spravato®.
Are you struggling with treatment-resistant depression and have tried multiple antidepressants with no success? Advanced Medical Psychiatry Group is here to help.
With Spravato®, many patients have experienced significant improvements in their symptoms in as little as four weeks. Plus, it’s covered by most major insurance providers.
Advanced Medical Psychiatry Group is proud to offer Spravato® at several locations nationwide. Don’t wait any longer to feel relief from persistent depression. Call today or book online to start feeling better soon.
What Is Spravato® (Esketamine)?
Spravato®, a nasal spray form of the medication esketamine, is used in conjunction with an oral antidepressant to treat certain cases of major depressive disorder (MDD), a form of depression. Spravato® is FDA-approved for use in adults with depression who have not responded to other treatments or those who have depression with thoughts of self-harm or suicide.
At Advanced Medical Psychiatry Group, your safety is our top priority. While Spravato® can be an appropriate treatment for severe depression, all patients treated at Advanced Medical Psychiatry Group must be able to maintain safety in the community. If you are having active thoughts of suicide or feeling unsafe, please seek help immediately at a crisis center or hospital.
How Does Spravato® Work?
Spravato® is an NMDA receptor antagonist which attaches to and blocks NMDA receptors in the brain. This raises levels of the neurotransmitter glutamate, leading to downstream processes that ultimately increase the growth and connectivity of brain cells (neurons).
Unlike many other medications for depression, Spravato® does not appear to work by inhibiting the reuptake of serotonin, norepinephrine, or dopamine. The precise way that Spravato® exerts its antidepressant effects remains under investigation.
Esketamine vs Ketamine
Esketamine is one form of the combination medicine ketamine. Ketamine is widely used in medicine for anesthesia and has also been used as a party drug. However, the doses of ketamine used to treat depression are much lower, and Spravato® is given in a controlled environment. Furthermore, ketamine is more potent than ketamine, meaning that a lower dose can be provided and side effects can be reduced. The amount and form of esketamine delivered in Spravato® can sometimes induce dissociation but is not high enough to produce intoxication or anesthesia.
What to Expect from Spravato® Treatment
A Spravato® treatment program comprises treatments administered in your Advanced Medical Psychiatry Group provider’s office. After helping the medication intranasally, trained staff will monitor you for at least two hours to ensure no severe side effects.
With Spravato® treatment, most patients can expect their depressive symptoms to improve quickly. In some cases, patients may even experience symptom relief within a few hours of their first treatment.
Spravato® treatments are typically administered twice a week for four weeks. After this period, your Advanced Medical Psychiatry Group provider may reduce the frequency of treatments or conclude them altogether. The duration and frequency of Spravato® treatment will depend on your symptoms and response to treatment.
Side Effects of Spravato®
Common side effects of Spravato® include nausea, dizziness, headache, and increased blood pressure. Spravato® can also cause sedation and dissociation, a feeling of detachment from oneself and one’s surroundings. Because of these risks, patients are monitored for at least two hours at the treatment center after administering the medication.
What Does Spravato® Treat?
The FDA approves Spravato® for use in adults with treatment-resistant depression or major depressive disorder with thoughts of self-harm or suicide. However, Spravato® is not for everyone, and you must talk with your healthcare provider to see if it is the right treatment option for you.
Good Candidates for Spravato® Treatment
You may be a good candidate for Spravato® treatment if you meet the following criteria:
You have been diagnosed with major depressive disorder or treatment-resistant depression.
You have not responded to other forms of treatment, such as psychotherapy, antidepressant medications, and lifestyle changes.
You have a major depressive disorder with thoughts of self-harm or suicide but can maintain your safety in the community. Depending on the severity of these thoughts, patients may require hospitalization.
You are 18 years old or older.
You are willing to comply with the safety measures recommended by your Advanced Medical Psychiatry Group provider. If you meet the criteria above and think Spravato® may be a promising treatment option, talk to your Advanced Medical Psychiatry Group provider. They can evaluate your symptoms and give you more information about how Spravato® or other treatment options can help manage your depression.
